title: Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [3H]2-furoyl-LIGRL-NH2, to human PAR2.
abstract: 1 To determine the binding characteristics of a highly potent agonist for protease-activated receptor-2 (PAR2), 2-furoyl-Leu-Ile-Gly-Arg-Leu-amide (2-furoyl-LIGRL-NH(2)), whole-cell binding assays were performed utilising a radioactive ligand, [(3)H]2-furoyl-LIGRL-NH(2). 2 Specific binding of [(3)H]2-furoyl-LIGRL-NH(2) was observed in NCTC2544 cells, dependent upon PAR2 expression, and competitively displaced by the addition of unlabeled PAR2 agonists. Scatchard analysis of specific saturation binding suggested a single binding site, with K(d) of 122+/-26.1 nM and a corresponding B(max) of 180+/-6 f mol in 3.0 x 10(5) cells. 3 The relative binding affinities of a series of modified PAR2 agonist peptides obtained from competition studies paralleled their relative EC(50) values for Ca(2+) mobilisation assays, indicating improved binding affinities by substitution with 2-furoyl at the N-terminus serine. 4 Pretreatment of cells with trypsin reduced specific binding of [(3)H]2-furoyl-LIGRL-NH(2), demonstrating direct competition between the synthetic agonist peptide and the proteolytically revealed tethered ligand for the binding site of the receptor. 5 In HCT-15 cells endogenously expressing PAR2, the binding of [(3)H]2-furoyl-LIGRL-NH(2) was displaced by addition of unlabeled ligands, Ser-Leu-Ile-Gly-Lys-Val (SLIGKV-OH) or 2-furoyl-LIGRL-NH(2). The relative binding affinity of 2-furoyl-LIGRL-NH(2) to SLIGKV-OH was comparable to its relative EC(50) value for Ca(2+) mobilisation assays. 6 The binding assay was successfully performed in monolayers of PAR2 expressing NCTC2544 and human umbilical vein endothelial cells (HUVEC), in 96- and 24-well plate formats, respectively. 7 These studies indicate that [(3)H]2-furoyl-LIGRL-NH(2) binds to human PAR2 at its ligand-binding site. The use of this radioligand will be valuable for characterising chemicals that interact to PAR2.
authors.affiliation: Tokyo New Drug Research Laboratories, Kowa Company Limited, Higashimurayama, 27 Taylor Street, Tokyo 189-0022, Japan. t-tanke@kowa.co.jp
authors.forename: Toru
authors.initials: T
authors.lastname: Kanke
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ishiwata
authors.forename: Mototsugu
authors.initials: M
authors.lastname: Kabeya
authors.forename: Masako
authors.initials: M
authors.lastname: Saka
authors.forename: Takeshi
authors.initials: T
authors.lastname: Doi
authors.forename: Yukio
authors.initials: Y
authors.lastname: Hattori
authors.forename: Atsufumi
authors.initials: A
authors.lastname: Kawabata
authors.forename: Robin
authors.initials: R
authors.lastname: Plevin
mesh_terms: D001665:Binding Sites; D001667:Binding, Competitive; D002118:Calcium / Q000378:metabolism; D002460:Cell Line; D045744:Cell Line, Tumor; D006801:Humans; D008024:Ligands; D009842:Oligopeptides / Q000378:metabolism*; D011869:Radioligand Assay; D044464:Receptor, PAR-2 / Q000819:agonists / Q000378:metabolism*; D013329:Structure-Activity Relationship; D014357:Trypsin / Q000378:metabolism
chemical_list: C487404:2-furoyl-LIGRLO-amide; D008024:Ligands; D009842:Oligopeptides; D044464:Receptor, PAR-2; D014357:Trypsin; D002118:Calcium